Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Study of Interpersonal Therapy and Complicated Grief Treatment in Adults 50 Years and Older

NCT01244295
View directory record Official record
Conditions
Complicated Grief
Interventions
Complicated Grief Treatment, Interpersonal Therapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 23, 2026, 8:24 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

NCT04127695
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ABBV-0805, Placebo ABBV-0805
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

NCT05814627
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
85
States / cities
Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT07673627
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
Interventions
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other · Combination Product
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Carlsbad, California • Miami, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

NCT01920854
View directory record Official record
Conditions
Kidney Failure, Chronic Therapy; Hemodialysis
Interventions
soluble ferric pyrophosphate, Placebo
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

NCT04199351
View directory record Official record
Conditions
Obesity
Interventions
AMG 171, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931
View directory record Official record
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
Cotadutide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

External Trigeminal Nerve Stimulation for Epilepsy

NCT01159431
View directory record Official record
Conditions
Epilepsy, Seizure Disorders
Interventions
Trigeminal Nerve Stimulation
Device
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 23, 2026, 8:24 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
Golcadomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
46
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

NCT02856802
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
Drug · Other
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

NCT04381988
View directory record Official record
Conditions
COVID-19, Cancer
Interventions
Hydroxychloroquine, Placebo, Radiation therapy
Drug · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Study of Different Doses of a Novel Treatment for Onychomycosis

NCT00679770
View directory record Official record
Conditions
Distal, Subungual Onychomycosis
Interventions
AN2690, 2.5%, AN2690, 5%, AN2690, 7.5%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Albuquerque, New Mexico • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

NCT03742973
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Coronado, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

NCT01116427
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
abatacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
20
States / cities
Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 23, 2026, 8:24 AM EDT
Active, not recruiting Phase 2 Interventional

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of CRD-740 in Heart Failure

NCT05409183
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
CRD-740, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Revive 24: A Study of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women With Peri-Menopausal Health Issues

NCT07117994
View directory record Official record
Conditions
Stress, Menopause, Fatigue, Sleep
Interventions
Radicle Revive Placebo Control Form 1, Radicle Revive Active Study Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
40 Years to 105 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

NCT00309322
View directory record Official record
Conditions
Anesthesia, Dental
Interventions
Phentolamine Mesylate (NV-101)
Drug
Lead sponsor
Novalar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2006 · Synced Oct 23, 2026, 8:24 AM EDT